Viatris (VTRS) Cash from Financing Activities (2019 - 2026)

Viatris' (VTRS) quarterly Cash from Financing Activities came in at -$203.8 million in Q1 2026, up 56.36% year-on-year from -$130.3 million in Q1 2025, and up 13.79% quarter-over-quarter from -$236.4 million in Q4 2025.

Viatris (VTRS) Cash from Financing Activities (2019 - 2026) Analysis & Trends

Viatris' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$203.8 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 56.36% year-over-year to -$203.8 million in Q1 2026; TTM through Mar 2026 was -$1.0 billion, a 76.42% increase from a year earlier, with the FY2025 full-year figure at -$1.3 billion, up 70.12% from the prior year.
  • Cash from Financing Activities climbed to -$203.8 million in Q1 2026 per VTRS's latest filing, from -$236.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at -$97.6 million in Q3 2023 and bottomed at -$1.6 billion in Q3 2024.
  • The 5-year median for Cash from Financing Activities is -$758.7 million (2022), against an average of -$706.3 million.
  • Across the five-year window, Cash from Financing Activities jumped 87.14% in 2023 and plunged 1576.95% in 2024, its largest moves.
  • Year by year, Cash from Financing Activities stood at -$1.3 billion in 2022, then surged by 30.4% to -$926.1 million in 2023, then slumped by 53.35% to -$1.4 billion in 2024, then surged by 83.35% to -$236.4 million in 2025, then increased by 13.79% to -$203.8 million in 2026.
  • Per Business Quant, the three latest VTRS Cash from Financing Activities figures stand at -$203.8 million (Q1 2026), -$236.4 million (Q4 2025), and -$228.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn -4.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -203.80 Mn
Mar 31, 2026 -203.80 Mn
Dec 31, 2025 -236.40 Mn
Dec 31, 2025 -236.40 Mn
Sep 30, 2025 -228.10 Mn
Sep 30, 2025 -228.10 Mn
Jun 30, 2025 -362.40 Mn
Jun 30, 2025 -362.40 Mn
Mar 31, 2025 -467.00 Mn
Mar 31, 2025 -467.00 Mn
Dec 31, 2024 -1.42 Bn
Dec 31, 2024 -1.42 Bn
Sep 30, 2024 -1.64 Bn
Sep 30, 2024 -1.64 Bn
Jun 30, 2024 -847.90 Mn
Jun 30, 2024 -847.90 Mn
Mar 31, 2024 -425.60 Mn
Mar 31, 2024 -425.60 Mn
Dec 31, 2023 -926.10 Mn
Dec 31, 2023 -926.10 Mn